Silibinin

(Redirected from Silymarin)
Jump to navigation Jump to search
Silibinin
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral Intravenous
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC25H22O10
Molar mass482.44 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Silibinin

Articles

Most recent articles on Silibinin

Most cited articles on Silibinin

Review articles on Silibinin

Articles on Silibinin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Silibinin

Images of Silibinin

Photos of Silibinin

Podcasts & MP3s on Silibinin

Videos on Silibinin

Evidence Based Medicine

Cochrane Collaboration on Silibinin

Bandolier on Silibinin

TRIP on Silibinin

Clinical Trials

Ongoing Trials on Silibinin at Clinical Trials.gov

Trial results on Silibinin

Clinical Trials on Silibinin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Silibinin

NICE Guidance on Silibinin

NHS PRODIGY Guidance

FDA on Silibinin

CDC on Silibinin

Books

Books on Silibinin

News

Silibinin in the news

Be alerted to news on Silibinin

News trends on Silibinin

Commentary

Blogs on Silibinin

Definitions

Definitions of Silibinin

Patient Resources / Community

Patient resources on Silibinin

Discussion groups on Silibinin

Patient Handouts on Silibinin

Directions to Hospitals Treating Silibinin

Risk calculators and risk factors for Silibinin

Healthcare Provider Resources

Symptoms of Silibinin

Causes & Risk Factors for Silibinin

Diagnostic studies for Silibinin

Treatment of Silibinin

Continuing Medical Education (CME)

CME Programs on Silibinin

International

Silibinin en Espanol

Silibinin en Francais

Business

Silibinin in the Marketplace

Patents on Silibinin

Experimental / Informatics

List of terms related to Silibinin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Silibinin (INN), also known as silybin (both from Silybum, the generic name of the plant from which it is extracted), is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin and others. Silibinin itself is mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio.Both in vitro and animal research suggest that silibinin has hepatoprotective (antihepatotoxic) properties that protect liver cells against toxins. Silibinin has also demonstrated in vitro anti-cancer effects against human prostate adenocarcinoma cells, estrogen-dependent and -independent human breast carcinoma cells, human ectocervical carcinoma cells, human colon cancer cells, and both small and nonsmall human lung carcinoma cells.

Chemically modified silibinin, silibinin dihydrogen disuccinate disodium (trade name Legalon SIL), a solution for injection, is currently being tested as a treatment of severe intoxications with hepatotoxic substances, such as death cap (Amanita phalloides) poisoning.There is also clinical evidence for the use of silibinin as a supportive element in alcoholic and child grade 'A' liver cirrhosis.

Pharmacology

Poor water solubility and bioavailability of silymarin led to the development of enhanced formulations. Silipide (trade name Siliphos), a complex of silymarin and phosphatidylcholine (lecithin), is about 10 times more bioavailable than silymarin. It has been also reported that silymarin inclusion complex with β-cyclodextrin is much more soluble than silymarin itself.There have also been prepared glycosides of silybin, which show better water solubility and even stronger hepatoprotective effect.

Silymarin is the first ingredient in several products sold as herbal telomerase activators, though the research demonstrating silymarin's effectiveness in this regard is proprietary and unpublished.

Silymarin, as other flavonoids, has been shown to inhibit P-glycoprotein-mediated cellular efflux. The modulation of P-glycoprotein activity may result in altered absorption and bioavailability of drugs that are P-glycoprotein substrates. It has been reported that silymarin inhibits cytochrome P450 enzymes and an interaction with drugs primarily cleared by P450s cannot be excluded.

Toxicity

A phase I clinical trial in humans with prostate cancer designed to study the effects of high dose silibinin found 13 grams daily to be well tolerated in patients with advanced prostate cancer with asymptomatic liver toxicity (hyperbilirubinemia and elevation of alanine aminotransferase) being the most commonly seen adverse event.

The compound is also devoid of embryotoxic potential in animal models.

Potential medical uses

A recent study suggested that silymarin may help patients with type II diabetes by assisting in blood sugar control.

Lab experiments on mice showed that silibinin protects the hepatic cells against the toxin alpha-amanitin which causes Amanita phalloides mushroom poisoning.

Biotechnology

Silymarin can be produced in callus and cells suspensions of Silybum marianum and substituted pyrazinecarboxamides can be used as abiotic elicitors of flavolignan production.

References